Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Profund Advisors LLC

Profund Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 61,076 shares of the biopharmaceutical company’s stock after acquiring an additional 23,304 shares during the period. Profund Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,426,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Rothschild Investment LLC boosted its stake in Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,520 shares during the period. Advisory Services Network LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $39,000. Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth approximately $40,000. Financial Life Planners bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $42,000. Finally, First Horizon Corp bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.25 on Thursday. The business has a 50 day moving average price of $26.55 and a two-hundred day moving average price of $24.57. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).